{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06273774",
            "orgStudyIdInfo": {
                "id": "8189-020"
            },
            "secondaryIdInfos": [
                {
                    "id": "MK-8189-020",
                    "type": "OTHER",
                    "domain": "Merck"
                }
            ],
            "organization": {
                "fullName": "Merck Sharp & Dohme LLC",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study of MK-8189 in Participants With Bipolar I Disorder (MK-8189-020)",
            "officialTitle": "A Multiple Dose Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MK-8189 in Participants With Bipolar I Disorder",
            "therapeuticArea": [
                "Mental Health"
            ],
            "study": "a-study-of-mk-in-participants-with-bipolar-i-disorder-mk"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-04-08",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-09-10",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-09-10",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-02-15",
            "studyFirstSubmitQcDate": "2024-02-15",
            "studyFirstPostDateStruct": {
                "date": "2024-02-23",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-21",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-22",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Merck Sharp & Dohme LLC",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The goal of this study is to evaluate the safety and tolerability of MK-8189 in participants with stable bipolar I disorder. There will be no hypothesis testing in this study."
        },
        "conditionsModule": {
            "conditions": [
                "Bipolar I Disorder"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "TRIPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 32,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Panel A: MK-8189 Dosing Regimen 1",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive MK-8189 once daily (QD) at dosing regimen 1 for up to 14 days.",
                    "interventionNames": [
                        "Drug: MK-8189"
                    ]
                },
                {
                    "label": "Panel B: MK-8189 Dosing Regimen 2",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive MK-8189 QD at dosing regimen 2 for up to 14 days.",
                    "interventionNames": [
                        "Drug: MK-8189"
                    ]
                },
                {
                    "label": "Panel C: MK-8189 Dosing Regimen 3",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive MK-8189 QD at dosing regimen 3 for up to 14 days.",
                    "interventionNames": [
                        "Drug: MK-8189"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Participants will receive MK-8189-matching placebo QD for up to 14 days.",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "MK-8189",
                    "description": "Oral Tablet",
                    "armGroupLabels": [
                        "Panel A: MK-8189 Dosing Regimen 1",
                        "Panel B: MK-8189 Dosing Regimen 2",
                        "Panel C: MK-8189 Dosing Regimen 3"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Oral Tablet",
                    "armGroupLabels": [
                        "Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of Participants Who Experience One or More Adverse Events (AEs)",
                    "description": "An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.",
                    "timeFrame": "Up to ~28 days"
                },
                {
                    "measure": "Number of Participants Who Discontinue Study Treatment Due to an AE",
                    "description": "An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.",
                    "timeFrame": "Up to ~14 days"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n* Meets diagnostic criteria for bipolar I disorder, manic or mixed features according to the Diagnostic and statistical manual of Mental Disorders TR (DSM-5 TR) and considered to be in a non-acute phase of their illness.\n* History of receiving and tolerating antipsychotic medication within the usual dose range employed for bipolar I disorder.\n* Body mass index is 18 and 40 kg/m\\^2, inclusive.\n* If currently taking an antipsychotic, is able to discontinue it's use at least 5 days prior to study start and the duration of the study.\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Untreated or uncompensated endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological abnormalities or diseases.\n* Evidence or history of a primary DSM-5 axis I psychiatric diagnosis other than those specified for inclusion.\n* History of cancer (malignancy).\n* Evidence or history of mental retardation, borderline personality disorder, or organic brain syndrome.\n* History of neuroleptic malignant syndrome or moderate to severe tardive dyskinesia.\n* Substance-induced psychotic disorder or behavioral disturbance.\n* DSM-5 TR defined substance use disorder within 3 months of screening.\n* History of seizure disorder beyond childhood or is receiving treatment with any anticonvulsant to prevent seizures.\n* Positive test(s) for hepatitis B surface antigen, hepatitis C antibodies or human immunodeficiency virus.\n* Major surgery or donation/loss of 1 unit of blood within 4 weeks prior to screening.\n* Received any vaccine starting from 30 days prior to study intervention or is scheduled to receive any vaccine through 30 days following study intervention.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "60 Years",
            "stdAges": [
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Toll Free Number",
                    "role": "CONTACT",
                    "phone": "1-888-577-8839",
                    "email": "Trialsites@merck.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Medical Director",
                    "affiliation": "Merck Sharp & Dohme LLC",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Woodland International Research Group-Clinical Research ( Site 0009)",
                    "status": "RECRUITING",
                    "city": "Little Rock",
                    "state": "Arkansas",
                    "zip": "72211",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "501-221-8681"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.74648,
                        "lon": -92.28959
                    }
                },
                {
                    "facility": "Atlanta Center for Medical Research ( Site 0001)",
                    "status": "RECRUITING",
                    "city": "Atlanta",
                    "state": "Georgia",
                    "zip": "30331",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "404-881-5800"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.749,
                        "lon": -84.38798
                    }
                },
                {
                    "facility": "Hassman Research Institute Marlton Site ( Site 0006)",
                    "status": "RECRUITING",
                    "city": "Marlton",
                    "state": "New Jersey",
                    "zip": "08053",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "267-981-8911"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.89122,
                        "lon": -74.92183
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Merck Clinical Trials Information",
                    "url": "http://www.merckclinicaltrials.com"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf",
            "url": "http://engagezone.msd.com/ds_documentation.php"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        }
    },
    "hasResults": false
}